Overview

Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)

Status:
Completed

Trial end date:
2011-07-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the receptor occupancy (RO) associated with telcagepant (MK-0974) administration based on displacement of [11C]MK-4232 from the CGRP receptors in the brain using PET. The study enrolled healthy participants (Part I) and migraine patients (Part III). Due to a protocol amendment, study Part II was not conducted.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Calcitonin
Calcitonin Gene-Related Peptide